Social networks
1,921Activities
Technologies
Entity types
Location
Milton Park Innovation Centre, 99 Park Dr, Milton, Abingdon OX14 4RR, UK
Milton
United Kingdom
Employees
Scale: 1 employee
Estimated: 18
Engaged corporates
2Added in Motherbase
7 months agoPioneering a novel macrophage conditioning approach to deliver breakthrough cancer therapies
Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of tumour-associated macrophages (TAMs). We are currently engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility across a broad spectrum of cancers. We are also more broadly interested in the potential to target GPR65 for benefit in a range of other serious diseases.
Pathios employs a cutting-edge scientific approach to mapping the signalling of key GPCRs on immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology. By leveraging a range of proprietary insights emerging from this approach Pathios has identfied GPR65 as a key innate immune checkpoint on TAMs and now aims to rapidly deliver on the promise of novel therapeutic agents targeting this receptor. We combine a team of experienced scientific leaders with a number of strategic external partnerships to efficiently carry out a range of drug discovery and scientific activities, capitalising on the very latest advances in GPCR drug discovery.
Pioneering a novel macrophage conditioning approach to delivering breakthrough cancer therapies
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
Bristol Myers Squibb Pharmaceutical, Pharmaceutical Manufacturing | Bristol Myers Squibb Pharmaceutical, Pharmaceutical Manufacturing | Other 18 Apr 2024 | | |
UK Atomic Energy Authority Research, National and local authorities | UK Atomic Energy Authority Research, National and local authorities | Other 26 Sep 2023 | |